△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Concepts
Follistatin-mediated muscle and body-composition improvement
Primary
Minicircle's Follistatin therapy is based on the causal claim that a non-viral plasmid carrying the human FST344 gene can cause host cells to express and secrete bioidentical human follistatin. Increased circulating follistatin is expected to support lean muscle, reduce body fat percentage, improve recovery or physical performance, and thereby improve healthspan-relevant measures such as body composition, vitality, metabolic markers, and well-being.
Testable predictions include increased circulating follistatin after treatment, increased lean mass on DEXA, reduced body fat percentage, changes in metabolic blood markers, improved self-reported well-being or recovery, and favorable shifts in epigenetic age markers compared with baseline or controls.
The core chain is biologically plausible: a plasmid carrying FST344 could enter host cells, express follistatin, and raise circulating follistatin. The weaker step is the jump from higher follistatin to broad healthspan claims. Lean mass and fat percentage are reasonable body-composition endpoints, but vitality, well-being, metabolic markers, and epigenetic age sit farther from the mechanism. One mouse lifespan result supports interest, but it does not prove the same construct produces durable, controlled benefit in humans.
Supporting evidence: The theory names a specific construct: a non-viral minicircle plasmid carrying the human FST344 gene.; The reasoning chain predicts a direct proximal biomarker: increased circulating follistatin after treatment.; A cited 2021 publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%.
Counter evidence: The evidence context gives no human trial results for DEXA lean mass, body fat percentage, metabolic markers, or epigenetic age.; Several downstream predictions have no supporting publication IDs.; The theory assumes biologically active tissue effects from circulating follistatin, but the provided evidence does not establish dose, duration, tissue exposure, or safety in humans.
Explanatory power4.0
The theory explains what should happen if the therapy works, but the supplied evidence gives little observed human change to explain. The mouse lifespan claim fits the follistatin hypothesis, yet it could also reflect species-specific effects, study conditions, altered muscle biology, metabolic changes, or other downstream effects that are not separated here. For human body composition, the explanatory claim remains mostly prospective.
Supporting evidence: The mechanism links plasmid delivery to FST344 expression, secreted follistatin, and measurable body-composition endpoints.; The reported 32.5% mouse lifespan extension is directionally consistent with a biologically meaningful follistatin effect.
Counter evidence: No controlled human outcomes are provided for lean mass, body fat percentage, recovery, performance, well-being, metabolic markers, or epigenetic age.; The evidence context does not compare the theory against exercise, diet change, placebo effects, baseline regression, training status, or other explanations for body-composition change.; Self-reported well-being and recovery are especially vulnerable to expectancy effects unless blinded controls are used.
Falsifiability8.0
This theory is testable in a clean way. If treatment does not raise circulating follistatin, the construct-level claim takes a direct hit. If follistatin rises but DEXA lean mass, body fat percentage, metabolic markers, performance, and recovery do not move against controls, the healthspan claim weakens sharply. The epigenetic-age prediction is less crisp because 'favorable' is undefined, but the main body-composition predictions can be measured.
Supporting evidence: The theory predicts increased circulating follistatin after treatment compared with baseline or controls.; It predicts increased lean mass on DEXA and reduced body fat percentage.; It predicts changes in metabolic blood markers and self-reported recovery or well-being.; It includes control-comparison language, which makes the predictions easier to test than baseline-only claims.
Counter evidence: The expected effect sizes, time windows, and success thresholds are not specified.; The epigenetic-age prediction is low confidence and underspecified.; Well-being and recovery endpoints need blinding and prespecified instruments to avoid soft positive reads.
Reasoning tree
premise
A non-viral minicircle plasmid carrying the human FST344 gene can be delivered to host cells as the initiating therapeutic construct.
medium confidence - 1 linked evidence item
assumption
assumes
Host cells that receive the FST344 minicircle plasmid will express the encoded human FST344 transgene.
medium confidence - 1 linked evidence item
derivation
implies
Expression of the human FST344 transgene causes host cells to secrete bioidentical human follistatin.
medium confidence - 1 linked evidence item
prediction
predicts
Circulating follistatin levels should increase after treatment compared with baseline or controls.
high confidence - 1 linked evidence item
assumption
assumes
Increased circulating follistatin is biologically active in tissues relevant to muscle, fat, recovery, performance, and metabolism.
medium confidence - 1 linked evidence item
derivation
implies
Biologically active follistatin is expected to support increased lean muscle mass.
medium confidence - 1 linked evidence item
prediction
predicts
DEXA scans should show increased lean mass after treatment compared with baseline or controls.
high confidence - 1 linked evidence item
project_implication
implies
If the predicted follistatin, DEXA, body-fat, metabolic, well-being, recovery, and epigenetic changes are observed, the therapy would support healthspan-relevant improvements in body composition, vitality, metabolic status, and well-being.
medium confidence - 1 linked evidence item
derivation
implies
Biologically active follistatin is expected to reduce body fat percentage.
medium confidence - 1 linked evidence item
prediction
predicts
Body-composition measurements should show reduced body fat percentage after treatment compared with baseline or controls.
high confidence - 1 linked evidence item
derivation
implies
Biologically active follistatin is expected to improve recovery or physical performance.
medium confidence - 1 linked evidence item
prediction
predicts
Participants should report improved well-being or recovery after treatment compared with baseline or controls.
medium confidence
prediction
predicts
Metabolic blood markers should shift favorably after treatment compared with baseline or controls.
medium confidence
prediction
predicts
Epigenetic age markers should shift favorably after treatment compared with baseline or controls.
low confidence
observation
observed_in
A supporting publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%.
medium confidence - 1 linked evidence item
Public endorsements
silent
There is no direct public statement here from Bryan Johnson endorsing, discussing, or disputing Minicircle's follistatin theory. The only theory-related items are third-party videos saying he underwent follistatin gene therapy or linking him to Minicircle. That is mention around him, not a public endorsement by him.
Glen C. Terry publicly says gene therapies "hold a great deal of promise for the future of medicine." That is a general positive statement about gene therapy, so it counts as a mention of the broader treatment approach. The supplied record does not show him publicly endorsing Minicircle's specific follistatin claim about lean mass, body fat, recovery, or healthspan measures.
FST344 expression improves body composition and healthspan markers
Primary
Minicircle's Follistatin therapy is based on the causal claim that a non-viral plasmid carrying the human FST344 follistatin gene can increase follistatin expression after subcutaneous administration, leading to higher lean mass, lower body fat percentage, improved vitality or well-being, and favorable metabolic or epigenetic changes. In the supplied material, the program explicitly measures circulating follistatin, DEXA body-composition outcomes, metabolic panels, epigenetic blood panels, and adverse events before and after treatment.
Testable predictions are that treated participants should show increased circulating follistatin after administration, increased lean mass, reduced body fat percentage, improved self-reported well-being or recovery, and favorable movement in metabolic or epigenetic-age assays compared with baseline or controls.
company website · Mon Jun 22 2026 12:23:46 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility6.0
The core premise is biologically credible: FST344 expression should raise follistatin, and higher follistatin can plausibly affect myostatin-related signaling and lean mass. The weaker step is delivery. The supplied material assumes a subcutaneous non-viral minicircle plasmid reaches relevant host cells and persists long enough to produce meaningful FST344 expression, but it does not give human expression data here. The metabolic, epigenetic-age, and well-being claims sit farther downstream, so they are plausible hypotheses rather than tight mechanistic consequences.
Supporting evidence: The program is built around a human FST344 follistatin gene delivered by a non-viral minicircle plasmid.; The reasoning chain predicts increased circulating follistatin after administration, then lean-mass effects through myostatin-related signaling.; A cited 2021 mouse study is titled "Follistatin plasmid therapy extends mouse lifespan by 32.5%".
Counter evidence: The key delivery premise is still an assumption: the plasmid must reach relevant host cells and persist long enough after subcutaneous administration.; The links to vitality, metabolic panels, and epigenetic-age assays are marked low confidence in the supplied reasoning nodes.; Mouse lifespan evidence does not by itself establish durable, beneficial FST344 expression in humans.
Follistatin-mediated muscle and vitality support
Primary
Minicircle's Follistatin therapy is presented as a non-viral plasmid gene therapy intended to increase or sustain follistatin expression in a way that supports lean muscle, recovery, vitality, and body composition. The implied causal theory is that raising follistatin activity can improve muscle-related physiology and thereby contribute to healthspan-relevant outcomes such as physical function and resilience.
Testable predictions would include increased lean mass, improved recovery or exercise performance metrics, favorable body-composition changes, and possibly changes in epigenetic-age measures after treatment compared with baseline or controls. The supplied material does not provide controlled clinical efficacy results, so this theory is extracted from company/product claims and testimonials rather than validated outcome data.
company website · Tue Jun 02 2026 04:37:41 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility6.0
The core biology is plausible: follistatin can affect muscle-growth pathways, and a plasmid therapy could in principle raise follistatin expression. The weak link is human delivery. The supplied evidence does not show that Minicircle's plasmid produces durable, biologically meaningful follistatin expression in treated people, so the premise rests on a credible mechanism plus an unproven implementation step.
Supporting evidence: The therapy is presented as a non-viral plasmid gene therapy intended to increase or sustain follistatin expression.; The causal chain states that increased follistatin activity should inhibit pathways that limit muscle growth or maintenance.; A supplied 2021 publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%.
Counter evidence: The delivered plasmid producing biologically meaningful follistatin expression in treated humans is marked as a low-confidence assumption.; The supplied material does not provide controlled clinical efficacy results in humans for Minicircle's Follistatin therapy.; Company claims and testimonials are treated as hypothesis-generating observations rather than validated outcome data.
Non-viral plasmid gene expression for healthspan modulation
Primary
Minicircle's platform theory is that introducing new genetic material into a person's cells using a non-viral, non-heritable plasmid can enhance selected biological functions relevant to longevity, performance, and wellness without using viral vectors or creating heritable genomic changes. In this framing, the causal intervention is transient or non-integrating expression of a therapeutic gene delivered subcutaneously through partner clinics.
Testable predictions include detectable expression or downstream activity of the encoded gene after treatment, measurable changes in target physiology, and an absence of heritable transmission. For longevity or healthspan applications, the company would predict improvements in wellness-linked biomarkers or functional outcomes rather than permanent genetic alteration.
company website · Sat May 30 2026 20:33:40 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility6.0
The core premise is biologically credible: plasmids can drive non-viral, non-heritable gene expression, and transient expression is a coherent goal. The weak point is delivery. Subcutaneous clinic delivery must reach enough relevant cells, at enough dose, for long enough, to change physiology in humans. The evidence supplied does not show that step.
Supporting evidence: The theory predicts detectable encoded-gene expression or downstream activity after treatment.; The theory explicitly avoids viral vectors and heritable genomic change, which fits the non-integrating plasmid frame.; A cited 2021 publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%.
Counter evidence: No human expression, biodistribution, dose-response, durability, or safety data are provided.; The key delivery assumption, that subcutaneous administration through partner clinics reaches enough relevant cells, is unsupported in the supplied evidence.; Mouse lifespan extension with follistatin does not establish broad healthspan modulation in humans.
Non-viral non-heritable plasmid delivery as a safer longevity platform
Minicircle's platform theory is that non-viral, non-heritable plasmid gene therapy can deliver longevity or wellness genes without using viral vectors and without making heritable genetic changes. The proposed causal route is platform-level: transient or non-integrating gene expression from plasmids should enable biologically active protein expression while reducing risks associated with viral delivery or germline transmission.
Testable predictions include detectable expression of the delivered therapeutic protein, absence of heritable transmission, an acceptable adverse-event profile under medical supervision, and measurable downstream effects tied to the specific gene payload, such as body-composition or biomarker changes for Follistatin and cognitive or health measures for Klotho.
company website · Wed Jun 24 2026 09:41:56 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility6.0
The core premise is biologically credible: plasmids can express proteins without viral vectors, and non-integrating delivery is a real safety advantage in principle. The weak point is dose and durability. A transient plasmid signal must still produce enough protein, in the right tissue, for long enough to move an aging-relevant endpoint. That is plausible payload by payload, but it is not yet a proven longevity platform in humans.
Supporting evidence: The theory predicts detectable expression of the delivered therapeutic protein, which is the right first mechanistic test.; The Follistatin plasmid mouse study reports a 32.5% lifespan extension, supporting the idea that a plasmid payload can produce a biological effect in animals.; The platform explicitly avoids viral vectors and heritable genetic modification, which matches a coherent safety rationale.
Counter evidence: The evidence context gives no human protein-expression data, dose-response data, tissue-distribution data, or durability data.; Non-heritable delivery is assumed rather than demonstrated here.; The Follistatin mouse result supports one payload in animals, not the whole platform across longevity genes.
Combined Klotho and Follistatin healthspan effects
Minicircle lists a combined Klotho and Follistatin non-viral plasmid gene therapy study, implying a causal theory that simultaneous delivery of these two genes may produce cognitive and health benefits in healthy adults. The mechanism supplied is limited to combined plasmid gene delivery of Klotho and Follistatin; no synergistic pathway is explicitly described in the material.
Testable predictions include acceptable safety in healthy volunteers and measurable improvements in cognitive outcomes, body-composition measures, metabolic or epigenetic markers, circulating follistatin, or other healthspan-relevant endpoints after combination therapy.
The starting claim is biologically possible but thin. Follistatin has mouse lifespan evidence in the supplied context, and Klotho is a plausible aging-related gene target, but the combined human claim rests on a large bridge: healthy adults, plasmid delivery, two genes at once, and cognitive plus broader healthspan effects. The weakest point is the missing joint mechanism. The material says the therapy delivers Klotho and Follistatin together, then assumes additive or complementary effects. That is a hypothesis, not a pathway.
Supporting evidence: Minicircle lists a combined Klotho and Follistatin non-viral plasmid gene therapy study in healthy adults.; Follistatin plasmid therapy has been reported to extend mouse lifespan by 32.5%.; The supplied mechanism is combined plasmid gene delivery of Klotho and Follistatin.
Counter evidence: No explicit pathway explains why Klotho and Follistatin should work better together.; The mouse Follistatin lifespan result does not directly establish human healthspan benefit in healthy adults.; The evidence context gives no human efficacy result for the combined therapy.
Explanatory power2.0
The theory explains very little yet because there is almost no observed combined-treatment evidence to explain. It can account for why a study would measure cognition, body composition, metabolic markers, epigenetic markers, and circulating follistatin, but it does not explain a demonstrated pattern of outcomes. Alternative explanations remain wide open: placebo response, regression to the mean, lifestyle changes, assay noise, or effects from one gene rather than the combination.
Klotho gene delivery for cognitive and healthspan benefits
Minicircle's Klotho program reflects the causal claim that non-viral plasmid gene therapy delivering Klotho may improve healthspan-relevant outcomes, including cognitive and broader health benefits, in healthy adults. The supplied material does not specify the downstream molecular mechanism, only that Klotho expression is the intended intervention target.
Testable predictions include measurable safety and efficacy signals in healthy adult volunteers receiving Klotho plasmid therapy, with potential improvements in cognitive measures and health-related biomarkers compared with baseline or controls.
The broad premise is credible: non-viral plasmid delivery can express an introduced gene, and Klotho is a plausible aging-relevant target. The weak point is the human chain. The supplied material gives no direct evidence that Minicircle's Klotho plasmid produces enough Klotho in healthy adults, for long enough, in the right tissues, to change cognition or healthspan biomarkers. The causal bridge from expression to benefit is mostly assumed.
Supporting evidence: A cited premise says non-viral plasmid gene therapy can deliver genes intended to affect healthspan-relevant biology.; The theory makes Klotho expression the intervention target, which is biologically plausible as a healthspan-related axis.
Counter evidence: The evidence context rates the assumption of biologically meaningful Klotho expression in healthy adults as low confidence.; The downstream molecular mechanism linking Klotho expression to cognition and healthspan benefits is unspecified.; The supplied publications do not directly establish Klotho plasmid therapy safety or efficacy in healthy adult humans.
Explanatory power2.0
The theory does not yet explain much observed human evidence because there is little relevant observed human evidence in the supplied record. It can explain why Minicircle would test Klotho delivery, but it does not explain demonstrated cognitive gains, biomarker shifts, or healthspan outcomes because those results are not shown here. Alternative explanations, including placebo effects, baseline variation, assay noise, or unrelated health changes, remain fully available.
Follistatin lifespan extension via plasmid gene therapy
Minicircle cites a causal theory that plasmid-mediated follistatin expression can extend lifespan, based on a listed 2021 study titled "Follistatin plasmid therapy extends mouse lifespan by 32.5%." In this theory, durable expression of follistatin from a plasmid gene therapy is not only a body-composition intervention but may influence aging biology sufficiently to increase lifespan.
Testable predictions include lifespan extension in treated animals, improved age-associated functional measures, and corresponding biomarker changes such as improved epigenetic age, metabolic markers, or body-composition measures after follistatin plasmid administration.
The core premise is biologically credible but thin. Follistatin can change muscle and body-composition biology by inhibiting myostatin and related TGF-beta family signals, so a plasmid therapy that raises follistatin could plausibly improve function in aging animals. The larger claim, that this changes aging biology enough to extend lifespan, rests here on one cited mouse-lifespan result and an assumption of durable, biologically meaningful expression. That is plausible. It is not yet sturdy.
Supporting evidence: The evidence context lists a 2021 study titled "Follistatin plasmid therapy extends mouse lifespan by 32.5%".; The theory makes a mechanistic bridge from durable follistatin expression to improved body composition and age-associated function.; The reasoning graph marks plasmid-mediated follistatin lifespan extension with medium confidence, not low confidence.
Counter evidence: The abstract, journal, source URL, dosing details, mouse strain, treatment age, and survival-curve context are missing.; The step from body-composition effects to broad aging biology is marked low confidence in the provided reasoning.; Durable expression from plasmid gene therapy is assumed rather than independently shown in the supplied context.
Explanatory power4.0
Combined Klotho and Follistatin expression may broaden healthspan effects
The supplied project list includes a combination Klotho and Follistatin plasmid gene therapy intended to investigate safety and efficacy, including cognitive and health benefits, in healthy adult volunteers. The causal theory is that delivering both transgenes by non-viral plasmid could combine the body-composition and vitality aims of Follistatin therapy with the cognitive and general health aims of Klotho therapy.
Testable predictions are that combination-treated participants should show measurable changes across both domains: follistatin-linked body-composition or vitality endpoints and Klotho-linked cognitive or general health endpoints, while maintaining acceptable safety.
The premise is biologically plausible in outline: Follistatin and Klotho are both credible aging-adjacent targets, and the theory makes a clear combined-expression claim. The weak point is delivery and translation. The supplied evidence supports Follistatin plasmid therapy in mice, but gives no direct support for Klotho plasmid expression in healthy adults, no evidence that both transgenes reach useful expression levels together, and no evidence that the two programs combine cleanly in humans.
Supporting evidence: The project list describes a non-viral plasmid therapy combining Klotho and Follistatin in healthy adult volunteers.; A cited 2021 publication reports that Follistatin plasmid therapy extended mouse lifespan by 32.5%.; The theory separates expected effects into body-composition or vitality endpoints for Follistatin and cognitive or general-health endpoints for Klotho.
Counter evidence: The Klotho premise has low-confidence support and no supporting publication in the supplied evidence graph.; The claim that non-viral plasmid delivery can produce meaningful expression of both factors in healthy adults is an assumption, not an observed result.; The evidence does not show that Klotho and Follistatin effects are additive or compatible when co-expressed.
Klotho plasmid expression supports cognitive and health benefits
Minicircle's Klotho programs are presented as injectable non-viral plasmid gene therapies intended to assess safety, efficacy, cognitive benefits, and broader health benefits in healthy adult volunteers. The causal claim extractable from the supplied material is that plasmid-mediated Klotho expression should produce measurable cognitive or healthspan-relevant benefits.
Testable predictions are that participants receiving Klotho plasmid therapy should show acceptable safety and measurable improvement on predefined cognitive or health endpoints compared with baseline or controls. The supplied material does not provide a detailed molecular pathway or results.
company website · Mon Jun 22 2026 12:23:46 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility4.0
The starting premise is biologically possible but thin. Klotho is a real longevity and cognition-related target, and plasmid delivery can in principle drive protein expression. The weak point is the missing bridge: the supplied material does not show that this Klotho plasmid produces biologically meaningful Klotho expression in healthy adults, or that the achieved expression level improves cognition or healthspan endpoints.
Supporting evidence: The program is described as an injectable non-viral plasmid gene therapy intended to express Klotho in healthy adult volunteers.; The theory makes a clear biological claim: plasmid-mediated Klotho expression should produce measurable cognitive or healthspan-relevant benefits.
Counter evidence: The supplied material does not provide a detailed molecular pathway linking plasmid-mediated Klotho expression to cognitive or healthspan benefits.; The key assumption that delivered plasmid will produce biologically meaningful Klotho expression has low confidence in the evidence graph.; Most cited minicircle publications concern DNA topology, mitochondrial minicircles, or minicircle biology rather than therapeutic Klotho expression or human health outcomes.
Follistatin plasmid therapy may extend lifespan
The supplied site analysis lists a 2021 publication titled "Follistatin plasmid therapy extends mouse lifespan by 32.5%." The explicit causal theory is that plasmid-mediated follistatin expression can affect organismal aging sufficiently to increase lifespan, at least in mice. The supplied material does not provide the paper URL, abstract, or detailed pathway, so the extractable mechanism is limited to follistatin plasmid therapy as the intervention and lifespan extension as the claimed outcome.
Testable predictions are that animals receiving comparable follistatin plasmid therapy should live longer than matched controls and should show measurable biological effects consistent with increased follistatin exposure.
The premise is biologically plausible at the surface: a plasmid can raise expression of a target protein, and the claimed intervention is tied to a concrete outcome, mouse lifespan. But the supplied evidence gives only a title, with no abstract, dosing, strain, sex, age at treatment, control design, survival curve, or pathway. That leaves the causal claim underbuilt. Our hypothesis is simple: follistatin exposure may have changed physiology in a way that affected survival, but we cannot tell whether that was aging biology, disease avoidance, body composition, experimental handling, or a smaller subset effect hidden inside the reported 32.5%.
Supporting evidence: A 2021 publication is listed with the title "Follistatin plasmid therapy extends mouse lifespan by 32.5%".; Follistatin plasmid therapy is identified as the intervention, and lifespan extension is identified as the claimed outcome.; The extractable causal theory predicts measurable biological effects consistent with increased follistatin exposure.
Counter evidence: The supplied material does not include the paper URL, abstract, experimental details, or biological pathway.; The causal attribution to increased follistatin exposure rather than unrelated experimental factors is listed as a low-confidence assumption.; No information is supplied about controls, sample size, mouse strain, sex, age, health status, or survival analysis.
Klotho-focused longevity modulation
Minicircle lists Klotho as a future therapy, implying a causal theory that plasmid-mediated expression of Klotho could be used for longevity or wellness applications. The supplied material does not describe the specific Klotho mechanism, target tissue, dosing, biomarkers, or expected clinical endpoints.
Testable predictions would depend on the company's eventual protocol but would likely require showing successful Klotho expression and downstream changes in healthspan- or aging-relevant biomarkers. Because the provided evidence only states that Klotho is coming in 2026, this mechanism should be treated as a low-detail company program claim rather than an articulated mechanistic theory.
company website · Tue Jun 02 2026 04:37:41 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility4.0
The premise is biologically plausible at a high level: Klotho is a credible longevity-relevant target, and plasmid-mediated expression is a real delivery concept. But this specific theory is thin. The supplied material gives no Klotho isoform, target tissue, dose, expression duration, biomarker panel, safety threshold, or clinical endpoint. That leaves the central causal chain mostly assumed.
Supporting evidence: Minicircle lists Klotho as a future therapy or program.; The proposed intervention is assumed to use plasmid-mediated expression to increase Klotho activity.; A prior Minicircle-associated plasmid therapy publication reported lifespan extension in mice using follistatin, which supports the broader platform context.
Counter evidence: The supplied material does not specify the Klotho mechanism, target tissue, dosing strategy, biomarkers, duration of expression, safety criteria, or expected clinical endpoints.; The cited lifespan-extension publication concerns follistatin, not Klotho.
Explanatory power2.0
This theory explains very little yet because there is almost no observed Klotho-specific evidence to explain. At most, it says: if plasmid delivery raises Klotho and Klotho changes aging-relevant biology, then a wellness or longevity effect might follow. That is a scaffold, not an explanation. Alternative explanations, such as ordinary program signaling by a company before protocol disclosure, fit the supplied facts just as well.
Non-viral plasmid delivery for transient, non-heritable enhancement
Minicircle describes its platform as non-viral, non-heritable plasmid gene therapy delivered subcutaneously through partner clinics. The causal theory is that plasmid-based delivery can introduce genetic material without viral vectors or inherited genomic modification, enabling expression of therapeutic proteins for longevity, performance, or wellness applications while avoiding some risks associated with viral or heritable approaches.
Testable predictions would include detectable expression of the intended transgene, absence of heritable transmission, acceptable safety and tolerability after subcutaneous administration, and measurable downstream biomarker or functional changes aligned with the encoded protein. The supplied material does not specify detailed delivery biology, biodistribution, duration of expression, or controlled safety data.
company website · Tue Jun 02 2026 04:37:41 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility6.0
The core premise is biologically credible: plasmid DNA can deliver genetic material without a viral vector, and transient protein expression is a real mechanistic possibility. The weak point is delivery. The supplied theory does not show that subcutaneous plasmid administration reaches enough relevant cells, for long enough, at a dose that gives useful protein expression without unacceptable risk.
Supporting evidence: The platform is described as non-viral, non-heritable plasmid gene therapy delivered subcutaneously through partner clinics.; A supplied publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%.; The reasoning model predicts detectable transgene expression after treatment.
Counter evidence: The supplied material does not specify delivery biology, biodistribution, duration of expression, or controlled safety data.; The assumption that subcutaneous plasmid delivery reaches sufficient target cells has low confidence.; The assumption that the encoded protein's effects are beneficial in the treated dose range has low confidence.
Klotho plasmid therapy as a longevity program
Minicircle lists Klotho as a forthcoming gene therapy program in the same plasmid gene therapy offering context. The explicit causal theory available from the provided material is limited: Klotho is being positioned as a longevity or wellness-relevant gene therapy target delivered through Minicircle's non-viral plasmid platform.
Because the material does not describe a specific Klotho mechanism, testable predictions can only be framed broadly: treatment would be expected to produce measurable Klotho-related activity and downstream changes in longevity- or wellness-associated biomarkers. The evidence provided does not specify which biomarkers, diseases, or functional outcomes Minicircle expects Klotho therapy to affect.
company website · Sat May 30 2026 20:33:40 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility4.0
The premise is biologically possible at a broad level: Klotho is being treated as a gene therapy target, and Minicircle's stated context is non-viral plasmid delivery. The weak point is specificity. The provided material gives no concrete Klotho mechanism, no target tissue, no dose logic, no expression-duration claim, and no named clinical endpoint. As stated, the theory is credible only as a loose program hypothesis, not as a worked biological model.
Supporting evidence: Minicircle lists Klotho as a forthcoming gene therapy program within its plasmid gene therapy offering context.; The delivery context is a non-viral plasmid gene therapy platform.
Counter evidence: The provided material does not specify a concrete biological mechanism for Minicircle's Klotho therapy.; The evidence does not identify which biomarkers, diseases, or functional outcomes Minicircle expects Klotho therapy to affect.
Explanatory power2.0
The theory explains very little beyond Minicircle's own positioning. It can say, in broad terms, that a plasmid program might raise Klotho-related activity and might affect wellness-linked biomarkers. That does not explain observed longevity effects, disease modification, functional improvement, or mechanism-specific biomarker changes, because none are supplied. Alternative explanations are simpler: Klotho may be listed because it is a recognizable longevity-associated gene, because it fits a platform menu, or because the program is still too early to have a defined claim.
Follistatin gene therapy for muscle, body composition, and aging biomarkers
Minicircle presents its Follistatin therapy as a non-viral, non-heritable subcutaneous plasmid gene therapy intended to support lean muscle, vitality, body composition, and epigenetic age. The causal theory is that delivering a Follistatin gene therapy changes physiology in a way that improves muscle-related performance and recovery, with downstream effects on body composition and aging-associated biomarkers.
Testable predictions include increased lean muscle or improved gym performance, faster recovery, improved body composition metrics, and favorable movement in epigenetic age measures after treatment. The provided materials include anecdotal claims of easier gym performance, stronger recovery, and rapid muscle gain, but no formal trial or publication evidence is supplied.
company website · Sat May 30 2026 20:33:40 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility4.0
The premise has a real biological hook: follistatin can affect muscle pathways, and a plasmid therapy could in principle express a protein after delivery. The weak point is delivery. The supplied theory assumes a subcutaneous, non-viral plasmid produces enough active follistatin in humans to change physiology, but that assumption is marked low confidence and has no supplied human clinical data behind it.
Supporting evidence: The therapy has a stated mechanism: deliver a follistatin gene therapy and increase follistatin activity.; The reasoning chain links increased follistatin activity to muscle performance, recovery, lean mass, and body composition.; One supplied publication title claims follistatin plasmid therapy extended mouse lifespan by 32.5%.
Counter evidence: No formal human trial or publication evidence is supplied for the therapy claims.; The key assumption, that subcutaneous plasmid delivery produces enough biologically active follistatin to alter human physiology, is assigned low confidence.; The mouse lifespan publication entry lacks an abstract, journal, and source URL.
Explanatory power4.0
The theory would explain a clean package of findings if follistatin rises first, lean mass increases, fat percentage falls, and downstream metabolic or epigenetic markers move in the same direction. Right now the supplied material mostly describes what will be measured, not what has been observed. Without controlled results, alternatives remain obvious: training, diet, regression to the mean, placebo effects for well-being, assay noise, and ordinary body-composition drift.
Supporting evidence: The proposed chain links a measured proximal marker, circulating follistatin, to DEXA body-composition outcomes.; The program measures metabolic panels, epigenetic blood panels, self-reported effects, and adverse events before and after treatment.; If follistatin rises before body-composition change, that temporal pattern would fit the causal claim.
Counter evidence: The evidence context does not report actual human outcome changes, effect sizes, controls, or durability.; Self-reported vitality and recovery are especially exposed to expectation effects unless blinded controls are present.; Metabolic and epigenetic-age assays can move for reasons unrelated to FST344 expression, including weight change, behavior change, inflammation, and measurement variance.
Falsifiability8.0
This theory is easy to wound with data. If treated participants do not show increased circulating follistatin after administration, the central delivery-expression claim takes a direct hit. If follistatin rises but DEXA lean mass and fat percentage do not move against baseline or controls, the body-composition claim weakens. The softer endpoints, vitality and epigenetic-age movement, are less clean, but the program has named measurable outputs.
Supporting evidence: The program measures circulating follistatin before and after treatment.; DEXA can test the predicted increase in lean mass and reduction in body fat percentage.; Metabolic panels, epigenetic blood panels, and adverse events are specified as measured outcomes.
Counter evidence: Some predictions use broad wording such as "favorable movement," which needs prespecified thresholds to prevent after-the-fact interpretation.; Well-being, vitality, and recovery are fuzzier endpoints unless the instruments and timing are fixed before analysis.; Baseline-only comparisons are weaker than randomized controls because lifestyle changes can mimic parts of the predicted pattern.
Reasoning tree
premise
A non-viral minicircle plasmid carrying the human FST344 follistatin gene is intended to increase follistatin expression after subcutaneous administration.
medium confidence - 1 linked evidence item
assumption
assumes
The administered plasmid reaches relevant host cells and persists long enough to produce biologically meaningful FST344 expression.
medium confidence - 1 linked evidence item
derivation
implies
Increased FST344 expression should raise circulating follistatin levels.
medium confidence - 1 linked evidence item
prediction
predicts
Treated participants should show increased circulating follistatin after administration compared with baseline or controls.
high confidence
observation
observed_in
The program measures circulating follistatin before and after treatment.
high confidence
project_implication
implies
If the predicted increases in follistatin and favorable body-composition, metabolic, epigenetic, and well-being changes are observed without unacceptable adverse events, the program would support the claim that FST344 expression improves body composition and healthspan markers.
medium confidence - 1 linked evidence item
observation
requires
The program measures adverse events before and after treatment to evaluate tolerability and safety signals.
high confidence
assumption
assumes
Changes in lean mass, body fat percentage, metabolic panels, epigenetic panels, and self-reported well-being are valid indicators of body-composition improvement and healthspan-relevant benefit.
medium confidence
derivation
implies
Higher follistatin is expected to inhibit myostatin-related signaling and thereby favor increased lean mass.
medium confidence - 1 linked evidence item
prediction
predicts
Treated participants should show increased lean mass compared with baseline or controls.
high confidence
observation
observed_in
The program measures DEXA body-composition outcomes before and after treatment.
high confidence
prediction
predicts
Treated participants should show reduced body fat percentage compared with baseline or controls.
high confidence
observation
observed_in
The program measures DEXA body-composition outcomes that can assess body fat percentage before and after treatment.
high confidence
derivation
implies
Improved body composition and follistatin-related effects are expected to improve vitality, well-being, or recovery.
low confidence - 1 linked evidence item
prediction
predicts
Treated participants should report improved well-being, vitality, or recovery compared with baseline or controls.
medium confidence
derivation
implies
FST344-driven body-composition changes are expected to produce favorable movement in metabolic markers.
low confidence - 1 linked evidence item
prediction
predicts
Treated participants should show favorable changes in metabolic panels compared with baseline or controls.
medium confidence
observation
observed_in
The program measures metabolic panels before and after treatment.
high confidence
derivation
implies
FST344 therapy may produce favorable movement in epigenetic blood-panel or epigenetic-age markers.
low confidence - 1 linked evidence item
prediction
predicts
Treated participants should show favorable movement in epigenetic-age assays compared with baseline or controls.
medium confidence
observation
observed_in
The program measures epigenetic blood panels before and after treatment.
The supplied Bryan Johnson quotes discuss immortality, skin aging, and an Akkermansia product. None mention Minicircle, follistatin, FST344 expression, lean mass, body fat, vitality, or metabolic or epigenetic effects. The video records say he underwent follistatin gene therapy, but they are third-party descriptions, not Johnson publicly stating or backing the theory himself.
Glen C. Terry publicly praises gene therapy in general, but the supplied record does not show him addressing Minicircle's specific FST344 follistatin claim. There is no attributed statement from him about increased follistatin, lean mass, body fat, vitality, or metabolic or epigenetic changes.
The theory can explain a narrow pattern if treated people gain lean mass or recover faster after follistatin expression rises. Right now, that pattern has not been shown in controlled human data. Testimonials, body-composition claims, and vitality language have easier explanations: training changes, diet, placebo effects, selection bias, measurement noise, or regression to the mean. The mouse lifespan result supports biological interest, but it does not explain human vitality claims.
Supporting evidence: The theory predicts increased lean mass, improved recovery or exercise performance metrics, and favorable body-composition changes.; The mouse study reports a 32.5% lifespan extension after follistatin plasmid therapy, giving preclinical support for biological activity.
Counter evidence: No controlled human efficacy results are supplied.; The link from improved muscle-related physiology to vitality, resilience, and healthspan outcomes is marked low confidence.; Epigenetic-age effects are only a low-confidence prediction, and the supplied material gives no controlled evidence for them.
Falsifiability8.0
This theory is easy to put in harm's way. A controlled trial could measure follistatin expression, lean mass, strength, recovery time, exercise performance, body composition, adverse events, and epigenetic-age markers before and after treatment. If expression does not rise, or expression rises without better muscle and function outcomes versus controls, the causal chain takes a direct hit.
Supporting evidence: The theory predicts increased lean mass compared with baseline or controls.; The theory predicts improved recovery or exercise performance metrics compared with baseline or controls.; The theory predicts favorable body-composition changes compared with baseline or controls.; The theory allows possible epigenetic-age changes after treatment compared with baseline or controls.
Counter evidence: Some claimed outcomes, such as vitality and resilience, need strict endpoint definitions before they can falsify anything.; Baseline-only comparisons would leave too much room for training, diet, expectation effects, and natural variation.
Reasoning tree
premise
Minicircle's Follistatin therapy is presented as a non-viral plasmid gene therapy intended to increase or sustain follistatin expression.
medium confidence - 1 linked evidence item
assumption
assumes
The delivered plasmid can produce biologically meaningful follistatin expression in treated humans.
low confidence
derivation
implies
Increased follistatin activity is expected to inhibit pathways that limit muscle growth or maintenance, thereby supporting lean muscle physiology.
medium confidence - 1 linked evidence item
derivation
implies
Improved muscle-related physiology could support recovery, vitality, body composition, and physical resilience.
low confidence
project_implication
implies
If the causal chain holds in humans, Follistatin therapy could be positioned as a healthspan intervention targeting physical function and resilience.
low confidence
prediction
predicts
Treated participants might show changes in epigenetic-age measures after treatment compared with baseline or controls.
low confidence
observation
observed_in
A supplied supporting publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%, providing preclinical support but not direct human efficacy evidence.
medium confidence - 1 linked evidence item
observation
requires
The supplied material does not provide controlled clinical efficacy results in humans for Minicircle's Follistatin therapy.
high confidence
assumption
assumes
Company claims and testimonials are treated as hypothesis-generating observations rather than validated outcome data.
high confidence
prediction
predicts
Treated participants should show improved recovery or exercise performance metrics compared with baseline or controls.
medium confidence
prediction
predicts
Treated participants should show favorable body-composition changes compared with baseline or controls.
medium confidence
prediction
predicts
Treated participants should show increased lean mass compared with baseline or controls.
The provided direct Bryan Johnson quotes are about plastic avoidance, nutrition, biomarker review, and the Enhanced Games, not Minicircle or follistatin therapy. The only follistatin-related items are third-party videos/claims describing him, which do not show Johnson himself publicly endorsing, mentioning, or contradicting this theory.
The provided evidence contains company and third-party materials about Minicircle and minicircle DNA technology, but none attributes any statement to Glen C. Terry about the follistatin-based muscle/vitality theory. With no direct quote, interview, post, or publication from him in the dossier, the evidence supports classifying him as silent rather than endorsing, mentioning, or contradicting it.
Explanatory power
4.0
The theory can explain a narrow result if plasmid follistatin expression truly caused the reported mouse lifespan extension. It does not yet explain the broader healthspan claim better than simpler alternatives, such as target-specific effects of follistatin, selection bias in wellness biomarkers, placebo effects in clinic settings, or ordinary short-term physiology shifts unrelated to aging biology.
Supporting evidence: The theory links gene expression to downstream physiological change, which is the right causal shape for a gene-expression intervention.; The mouse follistatin result gives one concrete example where plasmid expression could plausibly affect lifespan-linked biology.
Counter evidence: Only one relevant publication is supplied, and it concerns mouse follistatin rather than a general human longevity platform.; The evidence does not separate true healthspan modulation from narrower performance or biomarker effects.; No supplied human data connect treatment to durable functional outcomes.
Falsifiability8.0
This theory is quite testable. A clean study could look for encoded-gene expression, downstream target activity, target-physiology change, genome integration, and germline transmission. If treated people show no expression, no target physiology shift, or unexpected heritable transmission, the platform claim takes a direct hit.
Supporting evidence: The theory predicts detectable expression or downstream biological activity after treatment.; The theory predicts measurable changes in target physiology associated with the encoded gene.; The theory predicts no heritable transmission of the introduced genetic material.; For healthspan use, it predicts changes in wellness-linked biomarkers or functional outcomes.
Counter evidence: Some endpoints are vague: wellness-linked biomarkers can be chosen after the fact unless prespecified.; The claim covers longevity, performance, and wellness, which makes failure harder to pin down unless each indication has fixed endpoints.
Reasoning tree
premise
A non-viral, non-heritable plasmid can introduce new genetic material into a person's cells without using viral vectors or creating heritable genomic changes.
medium confidence
assumption
assumes
Subcutaneous delivery through partner clinics can deliver the plasmid to enough relevant cells to produce biologically meaningful gene expression.
medium confidence
derivation
implies
Because the plasmid is non-integrating or transient, the intervention is framed as temporary expression of a therapeutic gene rather than permanent genetic alteration.
medium confidence
assumption
assumes
The encoded therapeutic gene can enhance selected biological functions relevant to longevity, performance, or wellness.
medium confidence - 1 linked evidence item
observation
observed_in
A supporting publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%.
medium confidence - 1 linked evidence item
prediction
predicts
Treatment should produce measurable changes in the target physiology associated with the encoded gene.
high confidence - 1 linked evidence item
prediction
predicts
For longevity or healthspan applications, treatment should improve wellness-linked biomarkers or functional outcomes rather than permanently altering the genome.
medium confidence - 1 linked evidence item
prediction
predicts
After treatment, the encoded gene should show detectable expression or downstream biological activity.
high confidence
project_implication
requires
The platform's healthspan claim depends on demonstrating transient gene expression, target-physiology effects, and lack of heritable genomic change in treated people.
high confidence
prediction
predicts
The introduced genetic material should not be transmitted heritably.
The provided evidence does not include a direct Bryan Johnson quote endorsing or rejecting the theory. One third-party video summary says he underwent Minicircle-related follistatin gene therapy and claimed it was slowing his aging, which indicates public association with the idea but is weaker than a direct endorsement.
No public quotes, records, or publications were provided linking Glen C. Terry to this theory, so there is no evidence here of endorsement, mention, or contradiction.
Explanatory power4.0
The theory explains why a plasmid payload could change biology after delivery, but it does not yet explain much observed human evidence because the supplied evidence is thin. The mouse Follistatin result fits the theory, but alternative explanations remain open: a payload-specific muscle or endocrine effect, strain-specific animal biology, dosing effects, or study-specific artifacts. The platform claim is broader than the evidence can carry.
Supporting evidence: A reported 32.5% lifespan extension after Follistatin plasmid therapy is directionally consistent with biologically active plasmid expression.; The theory correctly requires payload-specific downstream endpoints, such as body-composition or biomarker changes for Follistatin and cognitive or health measures for Klotho.
Counter evidence: One animal payload result does not show that non-viral plasmid delivery is generally safer or effective as a longevity platform.; The context does not provide human biomarker changes, cognitive outcomes, adverse-event rates, or direct comparison with viral delivery.; The safety claim depends on absence of heritable transmission and acceptable adverse events, but those observations are not supplied.
Falsifiability8.0
This is the strongest Popperian feature. The platform makes concrete bets that can fail: no detectable protein expression, plasmid persistence where it should not persist, integration or heritable transmission signals, unacceptable adverse events, or no payload-specific downstream effect. A clean negative result on expression plus downstream biology would wound the platform claim badly.
Supporting evidence: The theory predicts detectable therapeutic protein expression.; It predicts no evidence of heritable transmission of the delivered plasmid or gene payload.; It predicts an acceptable adverse-event profile under medical supervision.; It predicts payload-specific effects, including body-composition or biomarker changes for Follistatin and cognitive or health-related effects for Klotho.
Counter evidence: The phrase acceptable adverse-event profile needs predefined thresholds before testing, otherwise the safety claim can drift after the fact.; Longevity and wellness endpoints can become soft unless the study locks primary endpoints, timing, assay methods, and comparison groups before dosing.
Reasoning tree
premise
Non-viral, non-heritable plasmid gene therapy is proposed as a longevity or wellness gene-delivery platform that avoids viral vectors and heritable genetic modification.
medium confidence
assumption
assumes
Delivered plasmids can remain transient or non-integrating in treated individuals rather than becoming inherited or permanently integrated into the genome.
medium confidence
prediction
predicts
Treatment should show no evidence of heritable transmission of the delivered plasmid or gene payload.
medium confidence
assumption
assumes
Transient or non-integrating plasmid expression can produce enough therapeutic protein to create biologically meaningful effects.
medium confidence - 1 linked evidence item
prediction
predicts
Treatment should produce detectable expression of the delivered therapeutic protein.
high confidence - 1 linked evidence item
prediction
predicts
Specific payloads should produce measurable downstream effects tied to their known biology, such as body-composition or biomarker changes for Follistatin.
medium confidence - 1 linked evidence item
observation
observed_in
A publication reports that Follistatin plasmid therapy extended mouse lifespan by 32.5%, supporting the plausibility that a plasmid payload can produce longevity-relevant biological effects in animals.
medium confidence - 1 linked evidence item
prediction
predicts
Klotho payload delivery should produce measurable cognitive or health-related effects if expression is sufficient and biologically active.
medium confidence
derivation
implies
If plasmids express therapeutic proteins without viral vectors or heritable changes, the platform should reduce risks associated with viral delivery and germline transmission.
medium confidence
prediction
predicts
Under medical supervision, the platform should have an acceptable adverse-event profile compared with higher-risk delivery approaches.
medium confidence
project_implication
requires
The platform should be evaluated payload by payload using protein-expression evidence, safety monitoring, heritability checks, and downstream biomarker or functional endpoints.
high confidence
project_implication
implies
Claims of safer longevity intervention remain provisional until human data show expression, non-heritability, acceptable adverse events, and payload-specific benefit.
The provided Bryan Johnson quotes talk about immortality, skin aging, and an Akkermansia product. None mention Minicircle, non-viral plasmid delivery, non-heritable gene therapy, or the safety claim behind this theory. The video records describe him from the outside, they are not his own public statements.
The public record ties Glen C. Terry to Minicircle's gene-therapy program, but not to a clear statement endorsing the specific theory that non-viral, non-heritable plasmid delivery is a safer longevity platform. His quoted statement supports gene therapy in general, and the linked trial record describes the plasmid approach as non-permanent and non-heritable at a site run by his organization. That is a public mention by association, not a direct theory-level endorsement.
Supporting evidence: The theory predicts measurable changes across cognitive, body-composition, metabolic, epigenetic, and circulating follistatin endpoints.; A Follistatin plasmid mouse lifespan signal gives one partial reason to test healthspan endpoints.
Counter evidence: No combined Klotho and Follistatin outcome data are provided.; No described synergy mechanism lets the theory distinguish combination effects from single-gene effects.; The supplied evidence does not show that cognitive or healthspan changes have occurred in treated healthy adults.
Falsifiability7.0
This theory is testable. A well-run healthy-adult study could refute the causal claim if plasmid delivery fails to alter circulating follistatin or other target-linked markers, if safety signals exceed acceptable limits, or if prespecified cognitive and healthspan endpoints do not improve against controls. The score is not higher because the endpoint list is broad. If every biomarker shift can count as support, the theory gets too much room to survive weak results.
Supporting evidence: The theory predicts acceptable safety in healthy volunteers.; It predicts measurable improvements in cognitive outcomes after treatment.; It predicts measurable improvements in body composition, metabolic or epigenetic markers, circulating follistatin, and other healthspan-relevant endpoints.
Counter evidence: The phrase other healthspan-relevant endpoints is broad enough to dilute a clean pass-fail test.; The material does not specify effect sizes, timing, primary endpoints, or the control comparison needed for a sharp falsification.
Reasoning tree
premise
Minicircle lists a combined Klotho and Follistatin non-viral plasmid gene therapy study in healthy adults.
medium confidence
premise
observed_in
Follistatin plasmid therapy has been reported to extend mouse lifespan by 32.5%.
medium confidence - 1 linked evidence item
assumption
assumes
Benefits observed from Follistatin plasmid therapy in mice may be relevant to healthspan endpoints in humans.
low confidence - 1 linked evidence item
premise
implies
The supplied mechanism is combined plasmid gene delivery of Klotho and Follistatin.
high confidence
observation
requires
No explicit synergistic pathway between Klotho and Follistatin is described in the provided material.
high confidence
assumption
assumes
Simultaneous delivery of Klotho and Follistatin may produce additive or complementary effects despite the absence of a described synergy mechanism.
low confidence
derivation
implies
If combined plasmid delivery successfully increases relevant gene-product activity, it may cause cognitive and broader healthspan benefits in healthy adults.
low confidence
prediction
predicts
Combination Klotho and Follistatin plasmid therapy will show acceptable safety in healthy volunteers.
medium confidence
project_implication
requires
The study should measure safety, cognitive outcomes, body composition, metabolic or epigenetic markers, circulating follistatin, and other healthspan-relevant endpoints to test the causal theory.
high confidence
prediction
predicts
Combination therapy will produce measurable improvements in cognitive outcomes after treatment.
low confidence
prediction
predicts
Combination therapy will produce measurable improvements in body-composition measures after treatment.
low confidence - 1 linked evidence item
prediction
predicts
Combination therapy will produce measurable changes in metabolic or epigenetic markers after treatment.
low confidence
prediction
predicts
Combination therapy will produce measurable changes in other healthspan-relevant endpoints after treatment.
low confidence
prediction
predicts
Combination therapy will increase or otherwise measurably alter circulating follistatin after treatment.
The provided evidence does not show Bryan Johnson publicly discussing the combined Klotho and Follistatin theory. His quoted statements cover immortality, skin aging, and an Akkermansia product, while the publication records are third-party descriptions of follistatin gene therapy and do not give a direct Johnson statement on the Klotho plus Follistatin combination or its claimed healthspan effects.
Glen C. Terry publicly praised gene therapy in general, saying it holds promise for medicine, but the supplied record does not show him endorsing, discussing, or disputing Minicircle's specific combined Klotho plus Follistatin theory. The clinical-trial record provided is also about follistatin alone, not the combined intervention.
Supporting evidence: The program has a coherent causal outline: plasmid delivery, Klotho expression, then possible cognitive or biomarker effects.; The theory produces expected outcome classes, including tolerability, cognitive measures, and health-related biomarkers.
Counter evidence: No supplied publication directly shows Klotho plasmid therapy improves cognition in healthy adults.; No supplied publication directly shows favorable healthspan biomarker changes after Klotho plasmid therapy in healthy adults.; Several cited publications concern minicircle DNA biology or unrelated minicircle contexts, not clinical Klotho efficacy.
Falsifiability7.0
The claim is testable. A controlled study could measure Klotho expression, adverse events, cognitive endpoints, and prespecified biomarkers after dosing. The theory would take a serious hit if treated volunteers showed no meaningful Klotho expression, no signal on cognitive or biomarker endpoints, or tolerability problems above an acceptable safety threshold. The current predictions still need sharper endpoints and time windows, but they can be made concrete.
Supporting evidence: The theory predicts measurable safety signals in healthy adult volunteers receiving Klotho plasmid therapy.; It predicts possible improvements in cognitive measures compared with baseline or controls.; It predicts favorable changes in health-related biomarkers compared with baseline or controls.
Counter evidence: The supplied prediction language uses broad terms like cognitive measures and health-related biomarkers without naming exact endpoints.; No effect size, follow-up duration, dose response, or failure threshold is specified.
Reasoning tree
premise
Non-viral plasmid gene therapy can be used as an intervention strategy to deliver genes intended to affect healthspan-relevant biology.
medium confidence - 1 linked evidence item
assumption
requires
A Klotho-encoding plasmid delivered by Minicircle's approach will produce biologically meaningful Klotho expression in healthy adult recipients.
low confidence
assumption
assumes
Increased Klotho expression is sufficient to influence cognitive or broader healthspan-relevant outcomes in healthy adults.
low confidence
derivation
implies
If Klotho plasmid delivery produces meaningful Klotho expression and Klotho causally affects healthspan biology, then the intervention may improve healthspan-relevant outcomes.
low confidence
project_implication
implies
Minicircle's Klotho program is premised on testing Klotho plasmid delivery as a possible healthspan intervention in healthy adults.
medium confidence
prediction
predicts
Healthy adult volunteers receiving Klotho plasmid therapy should show measurable safety signals compatible with tolerability.
medium confidence
prediction
predicts
Healthy adult volunteers receiving Klotho plasmid therapy may show improvements in cognitive measures compared with baseline or controls.
low confidence
prediction
predicts
Healthy adult volunteers receiving Klotho plasmid therapy may show favorable changes in health-related biomarkers compared with baseline or controls.
low confidence
observation
observed_in
The supplied supporting publications do not directly establish Klotho plasmid therapy efficacy or safety in healthy adult humans.
high confidence - 7 linked evidence items
assumption
assumes
The downstream molecular mechanism linking Klotho expression to cognitive and healthspan benefits is unspecified in the supplied material.
The supplied evidence does not show Bryan Johnson publicly discussing Minicircle's Klotho program or the claim that Klotho plasmid gene delivery improves cognition or broader healthspan in healthy adults. His quotes here cover immortality, skin aging, and Akkermansia, and the third-party records focus on Minicircle more generally and on follistatin gene therapy.
The record shows Glen C. Terry publicly praising gene therapies in general, but nothing here ties him to Minicircle's specific claim that Klotho plasmid delivery may improve cognition or broader healthspan outcomes in healthy adults. Broad enthusiasm for gene therapy is not a public endorsement of this Klotho theory.
The theory explains the listed mouse lifespan claim in a direct way: follistatin expression causes a survival benefit. But it does not yet beat simpler explanations, such as improved muscle mass, reduced frailty, altered metabolism, strain-specific effects, or study-design artifacts. The aging-biology layer is the weak link. Without epigenetic-age data, longitudinal biomarkers, pathology, and cause-of-death analysis, the theory explains the headline better than it explains aging.
Supporting evidence: The listed observation says treated mice had lifespan extension, and the theory predicts the same endpoint.; The theory also predicts improved age-associated functional measures and body-composition measures, which fit a follistatin mechanism.; The project implication correctly separates direct lifespan evidence from broader aging-biomarker hypotheses.
Counter evidence: The evidence context provides no biomarker results showing improved epigenetic age or broader aging-system change.; The broader claim that follistatin affects aging biology is marked low confidence.; Alternative explanations, especially muscle and frailty effects, remain viable from the supplied evidence.
Falsifiability8.0
This theory is easy to put at risk. Treat animals with follistatin plasmid, measure follistatin expression, compare survival against proper controls, then test function, body composition, metabolic markers, and epigenetic clocks. A clean null result on survival with confirmed expression would badly damage the lifespan claim. A survival effect with only muscle/body-composition changes and no aging-biomarker shift would narrow the theory to a frailty intervention.
Supporting evidence: The theory predicts lifespan extension in treated animals compared with controls.; It predicts improved age-associated functional measures after follistatin plasmid administration.; It predicts biomarker changes, including epigenetic age, metabolic markers, and body-composition measures.
Counter evidence: Some biomarker predictions are broad, so the theory could survive by moving between endpoints unless the tests are pre-specified.; The supplied context does not define the required expression level, treatment age, dose, mouse strain, or minimum effect size.; Aging-biology claims need controls that distinguish survival from reduced frailty or altered body composition.
Reasoning tree
premise
Plasmid-mediated follistatin expression can extend lifespan.
medium confidence - 1 linked evidence item
observation
observed_in
A listed 2021 study is titled "Follistatin plasmid therapy extends mouse lifespan by 32.5%" and is cited as evidence for lifespan extension in mice.
medium confidence - 1 linked evidence item
assumption
assumes
Durable expression of follistatin can be achieved from plasmid gene therapy at biologically meaningful levels.
medium confidence - 1 linked evidence item
derivation
implies
If plasmid gene therapy produces durable follistatin expression, then the intervention may affect aging biology rather than only body composition.
low confidence - 1 linked evidence item
derivation
implies
Changes in aging biology from follistatin expression could be sufficient to increase lifespan.
low confidence - 1 linked evidence item
project_implication
implies
A funding-discovery project should treat follistatin plasmid therapy as a testable longevity intervention candidate, while distinguishing direct lifespan evidence from broader aging-biomarker hypotheses.
medium confidence - 1 linked evidence item
prediction
predicts
Treated animals should show improved age-associated functional measures after follistatin plasmid administration.
medium confidence - 1 linked evidence item
prediction
predicts
Treated animals should show corresponding biomarker changes after follistatin plasmid administration.
medium confidence - 1 linked evidence item
prediction
predicts
Potential biomarker changes include improved epigenetic age measures.
low confidence - 1 linked evidence item
prediction
predicts
Potential biomarker changes include improved metabolic markers.
low confidence - 1 linked evidence item
prediction
predicts
Potential biomarker changes include improved body-composition measures.
medium confidence - 1 linked evidence item
prediction
predicts
Treated animals receiving follistatin plasmid administration should show lifespan extension compared with controls.
None of the provided Bryan Johnson quotes mention follistatin, plasmid gene therapy, Minicircle, or lifespan extension from follistatin. The provided video records make third-party claims about his treatment, but they are not Johnson's own public statements endorsing or disputing this theory.
The supplied record does not show Glen C. Terry publicly addressing the specific claim that follistatin plasmid gene therapy extends lifespan. His quoted statement supports gene therapy in general, but it does not mention follistatin, lifespan, or Minicircle's causal theory. The clinical trial record describes the intervention and study measures, not Terry's own view.
Explanatory power
3.0
The theory explains the project design more than it explains biological outcomes. If a trial measures both body-composition and cognitive endpoints, the combined-target rationale fits that design. But the supplied evidence contains no observed human benefit, no expression data, and no comparison against single-transgene arms. A simpler explanation is available: the project combines two popular candidate longevity factors because each has a separate rationale. That explanation needs fewer biological assumptions.
Supporting evidence: The observed project explicitly aims to investigate safety and efficacy, including cognitive and health benefits, in healthy adult volunteers.; The evidence graph links the combined theory to endpoint predictions across both Follistatin-linked and Klotho-linked domains.
Counter evidence: No human outcome data are supplied for the combination therapy.; No evidence shows that combination treatment explains any result better than Follistatin alone, Klotho alone, placebo effects, training effects, or baseline drift.; The Klotho-linked endpoint prediction has low confidence and no supporting publication in the supplied evidence.
Falsifiability7.0
The theory is testable. A trial can measure plasmid expression, Follistatin-linked body-composition or vitality endpoints, Klotho-linked cognitive or general-health endpoints, and adverse events. It would take a real hit if combination-treated participants showed no meaningful change in either endpoint family, if only one transgene expressed, or if safety problems blocked dosing. The prediction still needs tighter thresholds: 'measurable changes' and 'acceptable safety' must be defined before the data arrive, or the target can move too easily.
Supporting evidence: The theory predicts measurable changes in Follistatin-linked body-composition or vitality endpoints.; The theory predicts measurable changes in Klotho-linked cognitive or general-health endpoints.; The theory predicts acceptable safety while effects appear across both intended domains.
Counter evidence: The supplied prediction does not specify effect sizes, time windows, assay thresholds, or what adverse-event rate would count as unacceptable.; Without single-transgene comparators, the combination claim is harder to falsify cleanly because a positive result could come from only one component.
Reasoning tree
project_implication
Combined Klotho and Follistatin non-viral plasmid gene therapy may broaden healthspan effects by targeting both body-composition/vitality and cognitive/general-health domains in healthy adults.
medium confidence - 1 linked evidence item
premise
implies
Follistatin plasmid therapy is intended to influence body composition and vitality-related outcomes.
medium confidence - 1 linked evidence item
premise
implies
Klotho therapy is intended to influence cognitive and general health-related outcomes.
low confidence
assumption
assumes
Delivering both Klotho and Follistatin transgenes by non-viral plasmid can produce biologically meaningful expression of both factors in healthy adult volunteers.
medium confidence
assumption
assumes
The effects of Klotho and Follistatin expression can be combined without one therapy preventing or materially weakening the intended effects of the other.
medium confidence
derivation
implies
If Follistatin improves body-composition or vitality endpoints and Klotho improves cognitive or general-health endpoints, then co-expression should produce measurable changes across both endpoint domains.
medium confidence - 1 linked evidence item
prediction
predicts
Combination-treated participants should show measurable changes in follistatin-linked body-composition or vitality endpoints.
medium confidence - 1 linked evidence item
prediction
predicts
Combination-treated participants should show measurable changes in Klotho-linked cognitive or general-health endpoints.
low confidence
prediction
predicts
Combination-treated participants should maintain acceptable safety while showing changes across both intended healthspan domains.
medium confidence
observation
observed_in
The supplied project list includes a combination Klotho and Follistatin plasmid gene therapy intended to investigate safety and efficacy, including cognitive and health benefits, in healthy adult volunteers.
The supplied evidence shows Bryan Johnson talking about immortality, skin aging, and an Akkermansia product, and third-party videos say he underwent follistatin gene therapy. None of it shows him publicly discussing the specific theory that combining Klotho and Follistatin expression could produce broader healthspan effects.
The supplied record does not show Glen C. Terry publicly addressing the specific theory that combined Klotho and Follistatin plasmid expression could broaden healthspan effects. The only direct quote attributed to him is a general pro-gene-therapy statement, which is too broad to count as a mention or endorsement of this combined-transgene theory.
Explanatory power
2.0
The theory explains little at this stage because there are no reported cognitive, safety, or healthspan results to explain. A causal story can be proposed, but the supplied evidence does not show the observed pattern that Klotho plasmid expression supposedly accounts for. Right now, platform precedent and target plausibility are doing most of the work.
Supporting evidence: The theory would explain improved cognitive or healthspan endpoints if controlled studies showed higher Klotho expression followed by measurable benefit.; A separate follistatin plasmid therapy study is cited as precedent that plasmid-based gene therapy can have lifespan-relevant effects in mice.
Counter evidence: The supplied material does not provide trial results demonstrating cognitive, safety, or healthspan benefits for Klotho plasmid therapy.; The follistatin mouse study does not directly test Klotho or human cognition.; The cited minicircle literature mostly addresses DNA topology or minicircle biology, so it does not explain human Klotho outcomes.
Falsifiability7.0
The claim is testable. A controlled human study could measure Klotho expression, adverse events, cognitive endpoints, and healthspan-relevant endpoints before and after treatment. The theory would take a direct hit if the plasmid fails to raise Klotho, raises Klotho without benefit, or produces unacceptable safety signals.
Supporting evidence: The supplied predictions include acceptable safety compared with baseline or controls.; The supplied predictions include measurable improvement on predefined cognitive endpoints compared with baseline or controls.; The supplied predictions include measurable improvement on predefined healthspan-relevant endpoints compared with baseline or controls.
Counter evidence: The supplied material does not specify exact cognitive tests, healthspan endpoints, effect sizes, duration, or responder thresholds.; Without predefined endpoints and controls, vague claims of broader health benefits could survive failed readouts too easily.
Reasoning tree
premise
Minicircle's Klotho programs are injectable non-viral plasmid gene therapies intended to express Klotho in healthy adult volunteers and evaluate safety, efficacy, cognitive benefits, and broader health benefits.
medium confidence
assumption
assumes
The delivered Klotho plasmid will produce biologically meaningful Klotho expression in participants.
low confidence
derivation
implies
If plasmid-mediated Klotho expression is achieved, it should produce measurable cognitive or healthspan-relevant benefits.
low confidence
prediction
predicts
Participants receiving Klotho plasmid therapy should show measurable improvement on predefined cognitive endpoints compared with baseline or controls.
medium confidence
observation
requires
The supplied material does not provide trial results demonstrating cognitive, safety, or healthspan benefits for Klotho plasmid therapy.
high confidence
project_implication
requires
The theory should be evaluated through controlled human studies measuring Klotho expression, safety, cognitive endpoints, and healthspan-relevant endpoints rather than inferred from minicircle platform literature alone.
high confidence
prediction
predicts
Participants receiving Klotho plasmid therapy should show measurable improvement on predefined healthspan-relevant or broader health endpoints compared with baseline or controls.
medium confidence
observation
requires
The supplied material does not provide a detailed molecular pathway linking plasmid-mediated Klotho expression to cognitive or healthspan benefits.
high confidence
prediction
predicts
Participants receiving Klotho plasmid therapy should show acceptable safety compared with baseline or controls.
medium confidence
premise
implies
A separate follistatin plasmid therapy study is cited as precedent that plasmid-based gene therapy can produce lifespan-relevant effects in mice, but it does not directly test Klotho or human cognition.
low confidence - 1 linked evidence item
observation
observed_in
Most cited minicircle publications concern DNA topology, mitochondrial minicircles, or minicircle biology rather than therapeutic Klotho expression or human health outcomes.
The supplied evidence does not show Bryan Johnson publicly discussing Minicircle's Klotho plasmid program or claiming that Klotho expression improves cognition or broader health endpoints. The quotes cover immortality, skin aging, and an Akkermansia product. The video records discuss Minicircle and follistatin gene therapy, not Klotho.
Glen C. Terry publicly says gene therapies "hold a great deal of promise for the future of medicine." That is a general positive statement about gene therapy, including the category Minicircle operates in, but the supplied evidence does not show him endorsing the specific claim that Klotho plasmid expression improves cognition or broader health outcomes.
Explanatory power3.0
The theory explains one reported observation, treated mice lived longer by 32.5%, but it does not yet explain much else. A strong explanation would connect plasmid delivery to follistatin exposure, then to defined downstream biology, then to delayed mortality. The supplied material stops after intervention and outcome. Alternative explanations remain wide open: selection effects, strain-specific disease patterns, husbandry differences, plasmid dose effects unrelated to follistatin, or statistical noise. The theory is a candidate explanation, not yet the best one.
Supporting evidence: The listed publication title directly links follistatin plasmid therapy with a 32.5% mouse lifespan extension.; The theory predicts that treated animals should show biological effects consistent with increased follistatin exposure.; The claimed outcome is specific enough to invite comparison against matched controls.
Counter evidence: No mechanism is supplied beyond plasmid-mediated follistatin expression.; No abstract or pathway data are provided to show why follistatin should alter organismal aging rather than one narrower mortality driver.; The evidence context itself says the theory should be treated as minimally specified until the original paper and experimental details are obtained.
Falsifiability7.0
This theory is testable. Comparable follistatin plasmid treatment should extend survival versus matched controls, and treated animals should show evidence of increased follistatin exposure. A failed replication with verified expression would hit the causal claim hard. The score is not higher because the current statement lacks thresholds: how much expression, which tissues, what lifespan endpoint, what minimum effect size, and which mouse population would count as a fair test.
Supporting evidence: One stated prediction is that animals receiving comparable follistatin plasmid therapy should live longer than matched controls.; A second stated prediction is that treated animals should show measurable biological effects consistent with increased follistatin exposure.; The claimed effect size, 32.5% lifespan extension, gives a numerical benchmark for replication attempts.
Counter evidence: The supplied material does not define comparable therapy, including dose, vector design, route, schedule, or age at treatment.; No predefined biological marker of increased follistatin exposure is supplied.; No endpoint distinction is given between median lifespan, maximum lifespan, disease-free survival, or another survival measure.
Reasoning tree
premise
A 2021 publication is listed with the title "Follistatin plasmid therapy extends mouse lifespan by 32.5%".
high confidence - 1 linked evidence item
observation
observed_in
The supplied material does not include the paper URL, abstract, or detailed biological pathway for the follistatin plasmid therapy claim.
high confidence - 1 linked evidence item
project_implication
requires
The theory should be treated as minimally specified until the original paper, abstract, experimental details, and mechanism are obtained.
high confidence - 1 linked evidence item
premise
implies
Follistatin plasmid therapy is the intervention claimed to have extended mouse lifespan.
medium confidence - 1 linked evidence item
derivation
implies
Plasmid-mediated follistatin expression may influence organismal aging enough to increase lifespan, at least in mice.
low confidence - 1 linked evidence item
assumption
assumes
The reported lifespan extension is causally attributable to increased follistatin exposure from the plasmid therapy rather than unrelated experimental factors.
low confidence - 1 linked evidence item
prediction
predicts
Animals receiving comparable follistatin plasmid therapy should live longer than matched controls.
medium confidence - 1 linked evidence item
prediction
predicts
Animals receiving comparable follistatin plasmid therapy should show measurable biological effects consistent with increased follistatin exposure.
medium confidence - 1 linked evidence item
premise
implies
The claimed outcome is a 32.5% extension of mouse lifespan.
The supplied Bryan Johnson quotes talk about immortality, skin aging, and an Akkermansia product. None mention follistatin plasmid therapy or the claim that it extends lifespan. Two video records say he underwent follistatin gene therapy, but those are third party descriptions, not Johnson publicly endorsing the lifespan-extension theory himself.
The supplied record does not show Glen C. Terry publicly mentioning follistatin plasmid therapy, lifespan extension, or the 2021 mouse result. The only attributed quote is a general endorsement of gene therapies as promising for medicine, which is too broad to count as a public endorsement of this specific theory.
Supporting evidence: The theory proposes that successful and durable Klotho expression could modulate aging- or healthspan-relevant biology.; Future testing would need to show downstream biomarker changes consistent with Klotho activity.
Counter evidence: The supplied evidence only states that Klotho is coming in 2026.; No mechanism, endpoint, patient population, or Klotho-specific result is provided.; The broader plasmid-platform evidence comes from follistatin, which does not explain Klotho-specific longevity effects.
Falsifiability5.0
The claim can become testable, but the current version is under-specified. A real protocol could be falsified by failure to detect Klotho expression after administration, failure to move prespecified biomarkers, unacceptable safety findings, or no effect on defined clinical endpoints. Right now those tests are generic because the company has not named the dose, tissue target, assay window, or endpoint. The falsifiability is latent, not yet sharp.
Supporting evidence: A future protocol would need to show successful Klotho expression after plasmid administration.; A future protocol would need to show downstream changes in healthspan- or aging-relevant biomarkers consistent with Klotho activity.; A future protocol would need to define clinically meaningful endpoints before longevity or wellness benefits could be evaluated.
Counter evidence: The supplied material does not define dosing, biomarkers, duration of expression, safety criteria, or expected clinical endpoints.; Without prespecified thresholds, almost any weak biomarker movement could be narrated as partial support.
Reasoning tree
premise
Minicircle lists Klotho as a future therapy or program, but the supplied material provides only a minimal company claim rather than a detailed mechanistic rationale.
medium confidence
assumption
assumes
The proposed intervention would use plasmid-mediated expression to increase Klotho activity in a way relevant to longevity or wellness.
low confidence
derivation
implies
If plasmid-mediated Klotho expression can be achieved safely and durably, it could in principle modulate aging- or healthspan-relevant biology.
low confidence
prediction
predicts
A future protocol would need to show successful Klotho expression after plasmid administration.
medium confidence
prediction
predicts
A future protocol would need to show downstream changes in healthspan- or aging-relevant biomarkers consistent with Klotho activity.
medium confidence
observation
observed_in
The supplied material does not specify the Klotho mechanism, target tissue, dosing strategy, biomarkers, duration of expression, safety criteria, or expected clinical endpoints.
high confidence
project_implication
implies
Because the claim lacks mechanistic and protocol detail, it should be treated as a low-detail company program claim rather than an articulated mechanistic longevity theory.
high confidence
prediction
requires
A future protocol would need to define clinically meaningful endpoints before longevity or wellness benefits could be evaluated.
medium confidence
premise
observed_in
A prior Minicircle-associated plasmid therapy publication reports lifespan extension in mice using follistatin rather than Klotho, supporting the broader plasmid-therapy platform context but not the specific Klotho claim.
The supplied evidence shows Bryan Johnson discussing other topics and being linked to Minicircle/follistatin gene therapy, but it contains no direct public statement from him about Klotho, Klotho expression, or a Klotho-based longevity mechanism.
No supplied quote or record attributes any public statement by Glen C./Glenn Terry to Minicircle’s Klotho program. Publicly available references tie Glenn Terry to Minicircle’s follistatin work/GARM clinic role, not to Klotho, so there is no evidence here that he publicly endorses, mentions, or contradicts the Klotho-focused longevity theory.
Explanatory power4.0
The theory explains how a non-viral plasmid could produce an encoded protein, but it does not yet explain the harder outcomes: durable biomarker movement, functional benefit, safety, or longevity effects in treated humans. The mouse follistatin result supports the general idea that plasmid expression can matter biologically. It does not by itself explain Minicircle's clinic-delivered human claims.
Supporting evidence: The model links successful plasmid delivery to transient expression of an encoded therapeutic protein.; The supplied mouse study reports a 32.5% lifespan extension after follistatin plasmid therapy.; The theory predicts downstream biomarker or functional changes aligned with the encoded protein.
Counter evidence: No controlled human safety data are supplied.; No biodistribution or expression-duration data are supplied.; The leap from protein expression to longevity, performance, or wellness applications has low-confidence support.
Falsifiability8.0
This is the strongest Popperian dimension. The theory makes several claims that can fail cleanly: the intended transgene should be expressed, expression should stay non-heritable, subcutaneous delivery should be tolerable, and the encoded protein should move the expected biomarkers or functions. If treated subjects show no transgene expression, unexpected integration, poor tolerability, or no downstream signal, the theory takes a direct hit.
Supporting evidence: After treatment, the intended transgene should be detectably expressed.; The introduced genetic material should not be transmitted heritably.; Subcutaneous administration should show acceptable safety and tolerability.; Treatment should produce measurable downstream biomarker or functional changes aligned with the encoded protein.
Counter evidence: The supplied material does not define thresholds for expression level, duration, biodistribution, tolerability, or biomarker change.; Without pre-specified endpoints, a failed result could be softened after the fact by changing the claimed target tissue, dose, or time window.
Reasoning tree
premise
Minicircle's platform is described as non-viral, non-heritable plasmid gene therapy delivered subcutaneously through partner clinics.
medium confidence
premise
assumes
Plasmid-based delivery can introduce genetic material without using viral vectors.
medium confidence - 1 linked evidence item
derivation
implies
If plasmid DNA is delivered successfully into relevant cells, it may enable transient expression of an encoded therapeutic protein.
medium confidence - 1 linked evidence item
derivation
implies
Transient expression of therapeutic proteins could support longevity, performance, or wellness applications depending on the encoded protein.
low confidence - 1 linked evidence item
prediction
predicts
Treatment should produce measurable downstream biomarker or functional changes aligned with the encoded protein.
medium confidence - 1 linked evidence item
observation
observed_in
A supplied publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%.
medium confidence - 1 linked evidence item
assumption
requires
The encoded protein's biological effects are beneficial rather than harmful in the treated population and dose range.
low confidence
prediction
predicts
After treatment, the intended transgene should be detectably expressed.
high confidence - 1 linked evidence item
assumption
requires
Subcutaneous plasmid delivery reaches sufficient target cells to produce biologically meaningful protein expression.
low confidence
premise
assumes
Plasmid-based delivery can avoid inherited genomic modification.
medium confidence
derivation
implies
Avoiding viral vectors and heritable genomic modification may avoid some risks associated with viral or germline-modifying approaches.
medium confidence
prediction
predicts
The introduced genetic material should not be transmitted heritably.
high confidence
assumption
requires
Expression remains transient and does not integrate into the genome at clinically meaningful levels.
medium confidence
prediction
predicts
Subcutaneous administration should show acceptable safety and tolerability.
medium confidence
observation
contradicted_by
The supplied material does not specify detailed delivery biology, biodistribution, duration of expression, or controlled safety data.
high confidence
project_implication
implies
A credible development program would need direct evidence of transgene expression, non-heritability, biodistribution, expression duration, safety, tolerability, and downstream biomarker or functional effects.
The provided evidence contains no direct public statement from Bryan Johnson about Minicircle’s non-viral, non-heritable plasmid delivery theory. His quoted posts are about enhancement generally, monitoring, travel habits, and nutrition, while the Minicircle references are third-party video descriptions rather than Johnson’s own endorsement, mention, or contradiction of the theory.
The provided evidence contains company and third-party materials about Minicircle or minicircle DNA, but no attributable public statement, quote, or publication from Glen C. Terry addressing the theory. On this dossier, he is best classified as silent.
Supporting evidence: Klotho is being positioned as a longevity- or wellness-relevant gene therapy target delivered through Minicircle's plasmid platform.; If the therapy works as positioned, treatment should produce measurable Klotho-related activity.
Counter evidence: No provided observation shows that Minicircle's Klotho plasmid therapy changes aging biology, disease state, or functional outcomes.; The downstream biomarkers are unnamed, so the theory cannot explain a specific pattern of evidence better than alternatives.
Falsifiability3.0
The theory can be tested at the shallowest level: after treatment, Klotho-related activity should be measurable. That is a real prediction. The longevity claim is much softer. Without prespecified biomarkers, diseases, time windows, tissues, responder thresholds, or functional outcomes, almost any downstream change could be treated as supportive after the fact. A falsifiable version would need a defined expression target and named endpoints before dosing begins.
Supporting evidence: The provided prediction says treatment should produce measurable Klotho-related activity.; The project implication allows broad test plans focused on Klotho activity and downstream wellness biomarkers.
Counter evidence: The evidence does not specify which biomarkers, diseases, or functional outcomes should change.; The downstream prediction is framed as possible biomarker movement, which is too broad to cleanly refute the longevity program claim.
Reasoning tree
premise
Minicircle lists Klotho as a forthcoming gene therapy program within its plasmid gene therapy offering context.
medium confidence
premise
assumes
Minicircle's relevant delivery context is a non-viral plasmid gene therapy platform.
medium confidence - 1 linked evidence item
derivation
implies
Klotho is being positioned as a longevity- or wellness-relevant gene therapy target delivered through Minicircle's plasmid platform.
medium confidence
assumption
requires
The provided material does not specify a concrete biological mechanism for Minicircle's Klotho therapy.
high confidence
prediction
predicts
If the Klotho plasmid therapy works as positioned, treatment should produce measurable Klotho-related activity.
low confidence
prediction
predicts
If Klotho-related activity is induced, downstream changes may appear in longevity- or wellness-associated biomarkers.
low confidence
observation
observed_in
The provided evidence does not identify which biomarkers, diseases, or functional outcomes Minicircle expects Klotho therapy to affect.
high confidence
project_implication
implies
The Klotho program can currently support only broad, mechanism-agnostic test plans focused on Klotho activity and unspecified downstream longevity or wellness biomarkers.
The provided evidence shows Bryan Johnson discussing general health practices, biomarkers, and enhancement, plus third-party claims about Minicircle and follistatin gene therapy, but nothing in the dossier ties him to any public statement about Klotho specifically or Minicircle's Klotho plasmid therapy as a longevity program.
No provided quotes, records, or publications show Glen C. Terry publicly endorsing, mentioning, or contradicting the Klotho plasmid therapy longevity theory.
Explanatory power
2.0
The theory can explain the anecdotes if the therapy truly raises active follistatin enough to affect muscle physiology. That is a big if. Easier gym sessions, faster recovery, and rapid muscle gain also fit training changes, placebo effects, reporting bias, diet, supplementation, or regression to the mean. With anecdotes only, the theory does not beat those alternatives.
Supporting evidence: Provided materials include anecdotal claims of easier gym performance after treatment.; Provided materials include anecdotal claims of stronger recovery after treatment.; Provided materials include anecdotal claims of rapid muscle gain after treatment.
Counter evidence: The observations are anecdotal and low confidence.; No objective pre/post lean mass, strength, recovery, body composition, or epigenetic age dataset is supplied.; Most supplied publications about minicircles concern DNA topology or mitochondrial minicircle biology and do not directly support the claimed therapy effects.
Falsifiability8.0
This theory is easy to put at risk. A controlled study could measure lean mass, strength, recovery time, body composition, follistatin expression, and epigenetic age before and after treatment. If treated people fail to outperform controls on those endpoints, the core claim takes a direct hit. The current materials do not supply that test, but the prediction set is concrete enough to fail.
Supporting evidence: The theory predicts increased lean muscle mass after therapy.; The theory predicts improved gym performance after therapy.; The theory predicts faster recovery after exercise.; The theory predicts improved body composition metrics and favorable movement in epigenetic age measures.
Counter evidence: The supplied materials rely on anecdotes rather than a formal trial.; The theory text does not define effect sizes, timing windows, assay methods, or responder thresholds.
Reasoning tree
premise
Minicircle presents Follistatin therapy as a non-viral, non-heritable subcutaneous plasmid gene therapy intended to support lean muscle, vitality, body composition, and epigenetic age.
medium confidence
assumption
assumes
Subcutaneous plasmid delivery can produce enough biologically active follistatin expression to alter human physiology.
low confidence - 1 linked evidence item
derivation
implies
Increased follistatin activity is expected to modulate muscle-related pathways in a way that improves muscle performance and recovery.
low confidence - 1 linked evidence item
derivation
implies
Improved muscle performance and recovery are expected to produce downstream improvements in lean mass and body composition metrics.
low confidence
derivation
implies
Changes in muscle physiology and body composition are expected to move aging-associated biomarkers, including epigenetic age measures, in a favorable direction.
low confidence
prediction
predicts
Treated individuals should show favorable movement in epigenetic age measures after therapy.
medium confidence
observation
observed_in
The supplied publication set contains one apparently relevant preclinical claim about follistatin plasmid therapy extending mouse lifespan, but the provided entry lacks an abstract or source URL.
low confidence - 1 linked evidence item
prediction
predicts
Treated individuals should show increased lean muscle mass after therapy.
medium confidence
observation
observed_in
Provided materials include anecdotal claims of rapid muscle gain after treatment.
low confidence
prediction
predicts
Treated individuals should show improved body composition metrics after therapy.
medium confidence
prediction
predicts
Treated individuals should show improved gym performance after therapy.
medium confidence
observation
observed_in
Provided materials include anecdotal claims of easier gym performance after treatment.
low confidence
prediction
predicts
Treated individuals should report or demonstrate faster recovery after exercise.
medium confidence
observation
observed_in
Provided materials include anecdotal claims of stronger recovery after treatment.
low confidence
observation
contradicted_by
No formal human trial or publication evidence is supplied for the therapy claims in the provided materials.
high confidence
project_implication
requires
A project evaluating this theory should prioritize collecting objective pre/post measures of lean mass, strength or performance, recovery, body composition, and epigenetic age rather than relying on anecdotes.
high confidence
project_implication
implies
The evidentiary status should be treated as preliminary until formal human trial data or peer-reviewed clinical publications are available.
high confidence
observation
contradicted_by
Most supplied publications about minicircles concern DNA topology or mitochondrial minicircle biology and do not directly support Follistatin therapy effects on muscle, body composition, or aging biomarkers.
The provided direct Bryan Johnson quotes concern plastics, diet, medical monitoring, and the Enhanced Games, not Follistatin gene therapy or Minicircle's claimed effects on muscle, body composition, recovery, or aging biomarkers. The supplied Minicircle/Follistatin references are third-party video summaries rather than Johnson's own public endorsement or contradiction.
Glenn C. Terry is publicly listed as the corresponding author and a coauthor on Minicircle’s follistatin preprint, which states that the therapy safely improves body composition and lowers extrinsic epigenetic age; the paper also says he administered the therapy and that his clinic operates in commercial partnership with Minicircle.
